Org ID,NCT ID,Brief Title,Overall status,Agency,Gender,Minimum Age,Phase,Agency class,Study type,Study Design,Secondary ID,First received,Start Date,Completion date,Last changed date,Verification date,First received result date,PCD,Countries,IS FDA regulated,IS section 801CAMN107Y2101,NCT01456676,Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy,Completed,Novartis Pharmaceuticals,Both,18 Years,Phase 1,Industry,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",2011-000282-12,14-Oct-11,Jan-12,Feb-14,28-May-15,May-15,NULL,Feb-14,"CanadaFranceGermanyItalySpain",Yes,YesCLDE225A2112,NCT01769768,Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients,Recruiting,Novartis Pharmaceuticals,Both,18 Years,Phase 1,Industry,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",NULL,15-Jan-13,Apr-13,Nov-16,24-Jan-16,Jan-16,NULL,Nov-16,"United States",Yes,NoCLDE225A2201,NCT01327053,A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,"Active, not recruiting",Novartis Pharmaceuticals,Both,18 Years,Phase 2,Industry,Interventional,"Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment",2010-022629-14,30-Mar-11,Jun-11,Jul-16,14-Mar-16,Mar-16,24-Aug-15,Jun-13,"AustraliaBelgiumCanadaFranceGermanyGreeceHungaryItalySpainSwitzerlandUnited KingdomUnited States",Yes,YesCLDE225B2209,NCT01350115,"Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)",Completed,Novartis Pharmaceuticals,Both,18 Years,Phase 2,Industry,Interventional,"Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment",2010-023819-34,6-May-11,Apr-11,Oct-12,23-Sep-15,Sep-15,18-Aug-15,Oct-12,"AustriaBelgiumCanadaGermany",No,NULLCLDE225C2301,NCT01708174,A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB),"Active, not recruiting",Novartis Pharmaceuticals,Both,4 Months,Phase 2,Industry,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",NULL,11-Oct-12,May-13,Jul-16,11-Apr-16,Apr-16,NULL,Jul-16,"AustraliaBrazilCanadaFranceGermanyItalyNetherlandsRussian FederationSpainSwedenSwitzerlandUnited KingdomUnited States",Yes,NoCLDE225X1101,NCT01208831,An East Asian Study of LDE225,Completed,Novartis Pharmaceuticals,Both,18 Years,Phase 1,Industry,Interventional,"Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",NULL,21-Sep-10,Oct-10,Oct-13,20-Apr-16,Apr-16,NULL,Oct-13,"Hong KongJapanTaiwan",Yes,YesCLDE225X2101,NCT00880308,Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors,Completed,Novartis Pharmaceuticals,Both,18 Years,Phase 1,Industry,Interventional,"Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",2008-005603-26,9-Apr-09,Mar-09,Jul-13,27-Dec-14,Dec-14,NULL,Jul-13,"SpainSwitzerlandUnited KingdomUnited States",Yes,NoCLDE225X2103,NCT01487785,"Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients",Completed,Novartis Pharmaceuticals,Both,18 Years,Phase 1,Industry,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",2010-024218-70,5-Dec-11,Mar-12,Jul-14,24-Jan-16,Jan-16,NULL,Jul-14,"SpainUnited KingdomUnited States",Yes,NoCLDE225X2104,NCT01125800,A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB,Completed,Novartis Pharmaceuticals,Both,12 Months,Phase 1/Phase 2,Industry,Interventional,"Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",2010-019348-37,12-May-10,Feb-11,Oct-14,4-Feb-16,Feb-16,29-Sep-15,Oct-14,"AustraliaCanadaFranceItalyUnited KingdomUnited States",Yes,YesCLDE225X2114,NCT01576666,"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",Completed,Novartis Pharmaceuticals,Both,18 Years,Phase 1,Industry,Interventional,"Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label",2011-005016-28,10-Apr-12,Jul-12,Apr-15,18-Feb-16,Feb-16,NULL,Apr-15,"AustraliaBelgiumCanadaGermanyItalySpainUnited KingdomUnited States",Yes,NoCLDE225X2116,NCT01787552,A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF,"Active, not recruiting",Novartis Pharmaceuticals,Both,18 Years,Phase 1/Phase 2,Industry,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",2012-004023-20,6-Feb-13,May-13,Dec-16,17-Jun-16,Jun-16,NULL,Dec-16,"AustraliaBelgiumCanadaDenmarkFranceGermanyIrelandItalyNetherlandsSpainUnited Kingdom",No,NULLCLDE225X2203,NCT01826214,Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia,Completed,Novartis Pharmaceuticals,Both,18 Years,Phase 2,Industry,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment",NULL,25-Mar-13,May-13,May-15,25-May-16,May-16,14-Apr-16,May-15,"AustraliaAustriaBelgiumCanadaGermanyHungaryNetherlandsNorwaySpainUnited KingdomUnited States",Yes,NoCLDE225XUS20,NCT02002689,LDE225 for Patients With PTCH1 or SMO Mutated Tumors,Terminated,Novartis Pharmaceuticals,Both,18 Years,Phase 2,Industry,Interventional,"Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment",NULL,1-Dec-13,Feb-14,Mar-15,25-Apr-16,Apr-16,23-Mar-16,Mar-15,"United States",Yes,No